The two experimental treatments will continue on in more trials. //

From the trial's early data, 49% of patients given ZMapp died, as did 53% of those receiving remdesivir. By contrast, only 29% of patients treated with REGN-EB3 died, and only 34% of patients treated with mAb114 died.

The fatality rate of the current outbreak is estimated to be around 70%.

Moreover, when researchers looked at how patients fared when they sought treatment early in the disease progression, the drugs looked even better. Only 6% of those treated early with REGN-EB3 died, and 11% of those treated early with mAb114 succumbed to the disease. Mortality rates for early treatments with ZMapp and remdesivir were 24% and 33%, respectively.

Moving forward, researchers will only carry on with REGN-EB3 and mAb114 in further trials.